Ligand Pharmaceuticals | LGND - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Agenus USD 14.4M 19.26M 2025-12
Amgen USD 3.83B 130M 2026-03
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD -141.26M 182.07M 2026-03
Baxter International USD 66M 280.2M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Enviri Corporation USD -35.28M 61.58M 2025-12
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -200.28M 49.43M 2026-03
Intrexon USD -60.84M 26.62M 2024-06
Ionis Pharmaceuticals USD -118M 97M 2026-03
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Ligand Pharmaceuticals USD 60.33M 40.29M 2026-03
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD -1.88B 8.12B 2026-03
Pacira USD 4.62M 1.43M 2026-03
Pfizer USD 4.99B 340M 2026-03
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Veracyte USD 19.08M 5.55M 2026-03